InMed Pharmaceuticals Faces Nasdaq Delisting Challenge

InMed Pharmaceuticals ( (INM) ) just unveiled an update.

InMed Pharmaceuticals Inc. is facing potential delisting from the Nasdaq Capital Market for not meeting the minimum bid price requirement. The company has appealed this decision and has been granted a hearing with the Nasdaq Listing Qualifications Panel, scheduled for October 31, 2024. In the meantime, the appeal has postponed any delisting actions. The outcome of the hearing is uncertain, and there’s no assurance given that the company will be granted an extension to meet Nasdaq’s compliance requirements.

For detailed information about INM stock, go to TipRanks’ Stock Analysis page.